ABOUT COGNIZANT
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain. Our services and products, including the Cognizant® Shared Investigator Platform (SIP), are digitizing interactions between sponsors and investigators across every phase, helping the industry subtract time from clinical development and add it to patient lives. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. To learn more, visit cognizant.com/life-sciences.
VIDEOS
Learn how to overcome obstacles to collaboration that, when left unaddressed, lead to site selection and patient enrollment issues for sponsors and operational challenges for sites.
Industry experts from Eli Lilly and Cognizant share their perspectives on the process and building blocks of end-to-end clinical development, the essential elements of a unified clinical platform, and the benefits and challenges involved in realizing the vision of a unified clinical platform.
View this webinar to find out how the Cognizant® Shared Investigator Platform (SIP) automates the flow of documents connecting sponsor eTMF systems while enhancing site-sponsor collaboration, compounding efficiencies, and accelerating trials.
As clinical trials grow more complex, stakeholders urgently need to improve clinical trial efficiencies. Explore a solution for virtual monitoring, study oversight, and document exchange and collaboration, that enables sites, sponsors, and CROs to adapt to the new normal of conducting clinical trials virtually.
The Cognizant Shared Investigator Platform (SIP) supports a new, site-first approach for streamlining clinical trial processes. The industry’s first single-instance, multi-tenant SaaS solution, Cognizant SIP provides investigators and sponsors with a single technology platform from which they can collaborate and share documents, and harmonize workflows across the clinical trial lifecycle.
Discover how 7 of the top 15 global biopharmaceutical companies came together on a single clinical technology platform and operated through common workflows and common trial documents.
Cognizant Shared Investigator Platform (SIP) is a multi-sponsor collaborative solution for clinical trial site selection, start-up communications, and management. The open design of Cognizant SIP simplifies and accelerates clinical trials by eliminating redundant work for sponsors and clinical sites. This can lead to improved operating efficiencies, reduced costs of building and maintaining in-house technology, quicker study start up and more time spent with patients.
Seven of the top fifteen global biopharmaceutical companies are on a single clinical technology platform, leveraging one environment, operating via common workflows, documents and training.
CONTACT INFORMATION
Cognizant Technology Solutions
Glenpointe Centre West 500 Frank W Burr Blvd
Teaneck, NJ 07666
UNITED STATES
Phone: (267) 271-7288
Contact: Larissa Comis
BROCHURES
- Cognizant® SIP: Transform Clinical Trials: Efficient, Collaborative, Virtual
- eISF Solution Overview: Bridging The Path From Sponsor eTMF To Site eISF Systems
- The Cognizant® Shared Investigator Platform (SIP) Document Exchange Module
- Optimize Your Safety Notification Process With The Cognizant SIP Safety Exchange Module
- Seamlessly Connect Sponsor eTMF Systems And The Florence eISF
- Cognizant® Shared Investigator Platform
- Cognizant® Shared Investigator Platform Video Meetings
- Modernize Operations To Support A New Way Forward For Clinical Trials With Cognizant® SIP
- Cognizant® SIP: Transform Clinical Trials: Efficient, Collaborative, Virtual
FEATURED ARTICLES
-
![Clinical Supply Forecasting And Planning]( "Roche Cuts Feasibility Process by 36%")
Discover the solutions to how an industry pioneer and veteran biotech struggled with complexity and consistency when it came to its approach to clinical trial feasibility.
-
![iStock-1250270667-NK-natural-killer-cell-cancer]( "A Major Cancer Institution Shares Best Practices From Its Own Experience")
One leading oncology healthcare system and research institution has recently successfully implemented Cognizant SIP and shares, in this paper, its best practices around planning for and implementing Cognizant SIP given such a large footprint.
-
![Doctor with laptop clinical data iStock-1191691943]( "Implementing Cognizant® Shared Investigator Platform: Lessons From The Field")
Cognizant Shared Investigator Platform (SIP) is designed to streamline clinical trial site selection, start-up and operational management. One leading oncology healthcare system and research institution has recently successfully implemented Cognizant SIP and shares, in this paper, its best practices around planning for and implementing Cognizant SIP given such a large footprint.
-
![cognizantebook]( "SIP Support For The “New Normal” In The COVID-19 Crisis")
In the “New Normal,” Sponsors and sites collaborate remotely throughout the trial lifecycle by leveraging a solution that streamlines trial set-up and execution, leading to improved site experiences and faster time-to-market.
-
Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries.
-
![iStock-1196710425-450]( "It’ll Take New Tools And Partnerships To Fast-Track Clinical Trials For A COVID-19 R<sub>X</sub>")
The industry needs new tools, technologies, and partnerships to collaborate virtually on clinical trials for COVID-19 treatments.
-
![Clinical Trial]( "Accelerating Clinical Trials: The New And Future Normal")
Inefficient interactions between clinical trial stakeholders play a large role in the time to bring a new drug to market. The pandemic is forcing this to change. Cognizant is facilitating these efforts.
-
![Coronavirus vaccine, syringe COVID 19]( "Agile Drug Development Required In A New Age Of Urgency")
Why it’s time to reconsider the current drug development paradigm. Complementing traditional RCTs with accelerated RWE studies and real-time clinical analysis provides true benefits.
